Intellia Therapeutics: Promising Outlook with NTLA-2002’s Impressive Phase II Results and Competitive Edge
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...
Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
EurekAlert!14h
Gene editing approach paves the way to first-in-human clinical trial for rare genetic disease
A collaborative effort between investigators at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...
The American Journal of Managed Care14h
Sickle Cell Gene Therapies Face Unique Uptake Challenges
Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much ...
News Medical14h
Adenine base editors show potential to correct X-CGD-causing mutations
A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...
Why I Keep Buying These 14 Incredible Growth Stocks
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging ...
JD Supra17h
The Future of Food: Regulatory and Patent Landscape of Genome Editing in Food Technology
Our current food system is facing a myriad of critical challenges. The United Nations predicts that the world population will ...
Scientists use CRISPR tools to safely disable gene mutation linked to treatment-resistant melanoma
In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...
STAT1d
Does AI make patient portal responses better? Depends on who you ask
In an assessment of 9 clinics and 166 users spanning from nurses, medical assistants, and advanced practice clinicians to ...
Future Market Insights1d
Global Gene Editing Tool Market Set to Reach USD 3,713.1 Million by 2034, Driven by Growing Incidence of Genetic Diseases and R&D Advancements
The global gene editing tool market is expected to surge at a compound annual growth rate (CAGR) of 18.4% from 2024 to 2034, exceeding the previous growth rate of 17.4% (2019-2023). The market value ...
News Medical1d
Gene editing restores treatment sensitivity in melanoma
In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of ...